Cumberland Pharmaceuticals CEO and leadership

Mr. Kazimi has over twenty years' experience in the international biopharmaceutical industry. He has served as Chief Executive Officer and Chairman of the Board of Directors of Cumberland Pharmaceuticals, a specialty pharmaceutical firm headquartered in Nashville since the Company's inception in 1999. The Company was twice named to the Inc. 500 list of fastest growing private firms in the U.S. prior to its Initial Public Offering and listing on the NASDAQ stock exchange in 2009. More recently Cumberland was named one of the 40 fastest growing healthcare companies headquartered in the U.S. by Modern Healthcare Magazine in a listing that included hospital, physician, payers/insurers and supplier companies of all sizes. Prior to forming Cumberland, Mr. Kazimi served as President and Chief Operating Officer of Therapeutic Antibodies Inc., an international biopharmaceutical company. During his eleven years with the company, he oversaw operations in three countries and played a key role in the company's product development programs and licensing agreements. During his tenure the company completed over $100 million in financings culminating in an IPO on the London stock exchange. Earlier in his career, he worked at Brown-Forman Corporation, a Fortune 500 company rising through a series of management positions. Mr. Kazimi currently serves on the board of directors for the Nashville Health Care Council and Nashville Sports Council. He also serves as Chairman of CET a biomedical incubator and joint initiative among Cumberland, Vanderbilt University and the state of Tennessee's Technology Development Corporation He has previously served on the boards of the Tennessee Biotechnology Association and Aegis Sciences Corporation, a federally certified forensic toxicology laboratory. He holds a B.S. from the University of Notre Dame and an M.B.A. from the Vanderbilt Owen Graduate School of Management.

Mr. Martin E. Cearnal is a Senior Vice President and Chief Commercial Officer at CUMBERLAND PHARMACEUTICALS INC and is based in United States.

As Vice President of National Accounts, Mr. Herman handles all national sales, including wholesalers and retail chain buying offices, managed care home offices and federal government accounts. He also oversees corporate compliance efforts. Previously, he was with Solvay Pharmaceuticals where he served as Director of Managed Care, as well as Director of Trade Affairs and Customer Service. Earlier in his career, Mr. Herman spent eight years with Schwarz Pharma, where he held national sales leadership positions. He holds a B.S. from Indiana University and an M.B.A. from Cardinal Stritch University.

Mr. Kazimi has over twenty years' experience in the international biopharmaceutical industry. He has served as Chief Executive Officer and Chairman of the Board of Directors of Cumberland Pharmaceuticals, a specialty pharmaceutical firm headquartered in Nashville since the Company's inception in 1999. The Company was twice named to the Inc. 500 list of fastest growing private firms in the U.S. prior to its Initial Public Offering and listing on the NASDAQ stock exchange in 2009. More recently Cumberland was named one of the 40 fastest growing healthcare companies headquartered in the U.S. by Modern Healthcare Magazine in a listing that included hospital, physician, payers/insurers and supplier companies of all sizes. Prior to forming Cumberland, Mr. Kazimi served as President and Chief Operating Officer of Therapeutic Antibodies Inc., an international biopharmaceutical company. During his eleven years with the company, he oversaw operations in three countries and played a key role in the company's product development programs and licensing agreements. During his tenure the company completed over $100 million in financings culminating in an IPO on the London stock exchange. Earlier in his career, he worked at Brown-Forman Corporation, a Fortune 500 company rising through a series of management positions. Mr. Kazimi currently serves on the board of directors for the Nashville Health Care Council and Nashville Sports Council. He also serves as Chairman of CET a biomedical incubator and joint initiative among Cumberland, Vanderbilt University and the state of Tennessee's Technology Development Corporation He has previously served on the boards of the Tennessee Biotechnology Association and Aegis Sciences Corporation, a federally certified forensic toxicology laboratory. He holds a B.S. from the University of Notre Dame and an M.B.A. from the Vanderbilt Owen Graduate School of Management.

Mr. Kazimi has over twenty years' experience in the international biopharmaceutical industry. He has served as Chief Executive Officer and Chairman of the Board of Directors of Cumberland Pharmaceuticals, a specialty pharmaceutical firm headquartered in Nashville since the Company's inception in 1999. The Company was twice named to the Inc. 500 list of fastest growing private firms in the U.S. prior to its Initial Public Offering and listing on the NASDAQ stock exchange in 2009. More recently Cumberland was named one of the 40 fastest growing healthcare companies headquartered in the U.S. by Modern Healthcare Magazine in a listing that included hospital, physician, payers/insurers and supplier companies of all sizes. Prior to forming Cumberland, Mr. Kazimi served as President and Chief Operating Officer of Therapeutic Antibodies Inc., an international biopharmaceutical company. During his eleven years with the company, he oversaw operations in three countries and played a key role in the company's product development programs and licensing agreements. During his tenure the company completed over $100 million in financings culminating in an IPO on the London stock exchange. Earlier in his career, he worked at Brown-Forman Corporation, a Fortune 500 company rising through a series of management positions. Mr. Kazimi currently serves on the board of directors for the Nashville Health Care Council and Nashville Sports Council. He also serves as Chairman of CET a biomedical incubator and joint initiative among Cumberland, Vanderbilt University and the state of Tennessee's Technology Development Corporation He has previously served on the boards of the Tennessee Biotechnology Association and Aegis Sciences Corporation, a federally certified forensic toxicology laboratory. He holds a B.S. from the University of Notre Dame and an M.B.A. from the Vanderbilt Owen Graduate School of Management.

Mr. Martin E. Cearnal is a Senior Vice President and Chief Commercial Officer at CUMBERLAND PHARMACEUTICALS INC and is based in United States.